Cardiology Today


The following articles appeared in the print edition of CARDIOLOGY TODAY.

Table of Contents
Business of Cardiology

Cardiologist shortage on the horizon

L. Samuel Wann, MD, MACC, FESC

Cover Story

As controversy wanes, efforts shift to implementation of ACC/AHA guidelines

FDA News

FDA approves drug-coated angioplasty balloon catheter for PAD treatment

FDA advisory panel split on revote for LAA closure device

In the Journals

CHARISMA: Beta-blockers lowered CV events in patients with MI

Responses to mental stress differ between men, women with ischemic heart disease

Long-term survival, stroke rates similar between bioprosthetic, mechanical aortic valve replacement

Low-risk behaviors could prevent four of five MIs in men

Ezetimibe initiations declined, discontinuations increased after announcement of ENHANCE trial data

Oral contraceptive use had no beneficial, harmful effect in patients with long QT syndrome

Elderly patients more likely to adhere to generic statins than brand-name statins

Greater physical activity linked to lower rates of AF in postmenopausal women

TeleStroke units improved stroke care at rural hospitals

Strict glycemic control did not affect survival after CABG

Routine ECG screening discouraged for young people

Scientific statement encourages discussion of radiation risks before CV imaging

Industry News

Andexanet alfa achieved primary, secondary efficacy endpoints in phase 3 trial

Mount Sinai receives $1.1 million to assess heart, kidney disease in 9/11 responders

Meet the Board

Larry B. Goldstein, MD, FAAN, FANA, FAHA: A tireless advocate for stroke prevention

Meeting News Coverage

MORE-CRT: Quadripolar leads reduced risk for complications

Patiromer safe, effective for hyperkalemia, regardless of HF status

NOMI: Nitric oxide did not reduce infarct size in STEMI

PARTNER I: TAVR delivers mortality benefit, decreases rehospitalization at 5 years

SECURITY: 6-month DAPT performed similar to 12 months with DES implantation

Renal denervation failed to reduce MACE at 1 year

PARACHUTE III: Percutaneous ventricular restoration device safe in patients with ischemic dilated HF

Symplicity Flex: Renal denervation misses primary endpoint in patients with mild hypertension

Once-daily ZS-9 improved, maintained serum potassium levels in patients with HF, hyperkalemia

SIGNIFY: Ivabradine did not improve outcomes in stable CAD

MITOCARE: Investigational agent failed to prevent reperfusion injury in STEMI

CoreValve cost effective for high-risk patients undergoing TAVR

Beta-blockers failed to reduce mortality in patients with HF, AF

Biventricular pacing cost-effective for patients with atrioventricular block, left ventricular dysfunction

BRIGHT: Bivalirudin outperformed heparin alone, heparin plus tirofiban in PCI

CLP-1001 failed to improve symptoms, exercise performance in patients with HF

ACC changes recommendations on complete revascularization

ISAR TRIPLE: Shorter duration of triple therapy not superior to longer duration

FOCUS: Polypill improved adherence to treatment after MI

ENGAGE AF-TIMI 48: Edoxaban dose reduction improved clinical outcomes

AMIO-CAT: Amiodarone improved short-term recovery after AF ablation

Pharmacology Consult

The role of new PAH therapies

Melissa R. Meyer, PharmD; Karen J. McConnell, PharmD, FCCP, BCPS (AQ Cardiology)

Trial Scorecards

Trial Scorecard: EXCITE ISR

Trial Scorecard: PARACHUTE III

Trial Scorecard: CLEAN-TAVI

Trial Scorecard: AMIO-CAT

Trial Scorecard: BRIGHT

Trial Scorecard: CHARISMA

Trial Scorecard: COPPS-2

Trial Scorecard: BLOCK-HF